Loading...
Market
First Alzheimer's drugmaker to address withholding genetic risk info by Mar 31, 2025?
4
Resolution / Starting Odds
Drugmaker A • 25%
Drugmaker B • 25%
Drugmaker C • 25%
None • 25%
Press releases or public statements from the companies
Story
Alzheimer's Drugmakers Withheld Genetic Risk Information from Trial Participants and Families
Oct 24, 2024, 01:44 AM
Alzheimer's drugmakers did not inform trial participants and their families that genetic tests showed they were at high risk for brain bleeds. Participants were required to sign consent forms acknowledging the risk of brain injuries due to certain genetic profiles and that they would be tested, but the results were not disclosed to them. This has raised ethical concerns and questions about the role of private-equity backed IRB boards in the trials. One observer noted, 'It’s not even a matter of ethics, it’s a matter of common sense.'
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lecanemab • 25%
Aducanumab • 25%
Another new drug • 25%
No approval • 25%
Yes • 50%
No • 50%
